FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
UNITED STATES SECURITIES AND EXCHANGE...
As filed with the Securities and Exchange Commission on August 8, 2019 Registration No...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wa...
Announced Rebranding and Name Change to Lineage Cell Therapeutics and Corporate Relocation Awarded $2.5 Million Grant from the Israel Innovation...
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs...
New Identity Reflects Commitment to Becoming a Leading Cell Therapy Company Company to Trade on NYSE American Under Ticker “LCTX” at Market Open...
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today...
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.